As of July 2026, Eli Lilly has not yet submitted the New Drug Application for retatrutide
After three to four weeks, patterns emerge that no amount of general advice can replicate
10.1080/15548627.2019.1615823 12 CelardoI.CostaA
Retatrutide (2026) Semaglutide Mechanism: GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: 1520% body weight Administration: Weekly injection Onset: Appetite changes within first few weeks Cost: Membership pricing at Better Med Spa see plans Tirzepatide Mechanism: Dual GIP + GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: Up to 22% body weight Administration: Weekly injection Onset: Often faster appetite suppression Cost: Membership pricing at Better Med Spa see plans Retatrutide Mechanism: Triple agonist (GLP-1 + GIP + Glucagon) FDA Status: NOT approved investigational only Expected Weight Loss: Early data suggests very potent effects (up to 24% in trials) Administration: Weekly injection (investigational protocols) Onset: Under investigation Cost: Not yet available What Are Semaglutide, Tirzepatide, and Retatrutide
To enhance vision health and potentially reduce the occurrence of black spots or floaters, it is advisable to use glutathione eye drops as directed by a healthcare professional
The increased gallstone risk may be attributable to two mechanisms: the rapid and substantial weight loss these medications facilitate, and potentially direct effects of GLP-1 agonists on reducing gallbladder motility and emptying
